About Ethylmalonyl-CoA decarboxylase
Ethylmalonyl-CoA decarboxylase (ECHDC1) is a protein
from Homo sapiens identified by UniProt accession
Q9NTX5, 307 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | Ethylmalonyl-CoA decarboxylase |
|---|
| UniProt accession | Q9NTX5 |
|---|
| Gene | ECHDC1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 307 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (115)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.39
- short chain acyl-CoA dehydrogenase deficiency · score 0.36
- mean reticulocyte volume · score 0.29
- breast disease · score 0.28
- breast carcinoma · score 0.23
- high density lipoprotein cholesterol measurement · score 0.12
- triglyceride measurement · score 0.11
- C-reactive protein measurement · score 0.11
- serum albumin measurement · score 0.11
- waist-hip ratio · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NTX5-F1 | alphafold | PREDICTED | 90.78 | — |
Amino-acid sequence (307 residues)
MALKQEMAKS LLKTASLSGR TKLLHQTGLS LYSTSHGFYE EEVKKTLQQF PGGSIDLQKE DNGIGILTLN NPSRMNAFSG VMMLQLLEKV IELENWTEGK GLIVRGAKNT FSSGSDLNAV KSLGTPEDGM AVCMFMQNTL TRFMRLPLIS VALVQGWALG GGAEFTTACD FRLMTPESKI RFVHKEMGII PSWGGTTRLV EIIGSRQALK VLSGALKLDS KNALNIGMVE EVLQSSDETK SLEEAQEWLK QFIQGPPEVI RALKKSVCSG RELYLEEALQ NERDLLGTVW GGPANLEAIA KKGKFNK
Explore Ethylmalonyl-CoA decarboxylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets